Lorlatinib bij ALK+/ROS1+ NSCLC

Delen via:
WCLC 2017

Log hier in om volledige toegang te krijgen.

Login of Account maken

 

Bronnen:
Solomon BJ, Shaw A, Ignatius Ou S-H, et al. Phase 2 Study of Lorlatinib in Patients with Advanced ALK/ROS1 Non-Small-Cell Lung Cancer. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 05.06.